【摘要】：目的探討帕羅西汀聯(lián)合小劑量齊拉西酮對女性抑郁癥療效及安全性評價(jià)。方法選取收治的110例女性抑郁患者,分為對照組和觀察組,對照組使用帕羅西汀單獨(dú)治療,觀察組使用帕羅西汀和小劑量齊拉西酮聯(lián)合治療,對比觀察兩組患者的臨床療效、漢密斯頓抑郁量表(HAMD)評分和不良反應(yīng)。結(jié)果兩組患者經(jīng)8周治療后,對照組患者總有效率為63.64%,觀察組患者總有效率為83.64%,對照組總有效率明顯低于觀察組,差異有統(tǒng)計(jì)學(xué)意義(醊2=5.666 2,P0.05);治療前對照組與觀察組患者的HAMD評分值之間差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療2、4、6周后,觀察組的HAMD評分值與對照組比較差異有統(tǒng)計(jì)學(xué)意義(P0.01),治療8周后兩組患者的HAMD評分值之間差異無統(tǒng)計(jì)學(xué)意義(P0.05)。對照組與觀察組均無明顯的不良反應(yīng)產(chǎn)生。結(jié)論帕羅西汀聯(lián)合齊拉西酮治療抑郁癥具有較好的臨床療效,治療周期短,安全性高,無不良發(fā)應(yīng),值得臨床推廣。
[Abstract]:Objective to evaluate the efficacy and safety of paroxetine combined with low dose ziprasidone in the treatment of female depression. Methods 110 female patients with depression were divided into control group and observation group. The control group was treated with paroxetine alone, the observation group was treated with paroxetine and low dose ziprasidone, and the clinical efficacy of the two groups was compared. Hamilton depression scale (HAMD) score and adverse reactions. Results after 8 weeks of treatment, the total effective rate was 63.64% in the control group and 83.64% in the observation group. The total effective rate in the control group was significantly lower than that in the observation group (鈮，

本文編號：2476584